Side-by-side · Research reference
CJC-1295 (no DAC)vsSemaglutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 1Reviewed15/51 cited
BFDA-ApprovedVerified15/53 cited
CJC-1295 (no DAC)
Short-acting GHRH · No DAC variant
SQ · Pre-sleep · 1–2×/day
Semaglutide
GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
01Mechanism of Action
Parameter
CJC-1295 (no DAC)
Semaglutide
Primary target
Pituitary GHRH receptorTeichman 2006
GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021
Pathway
GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosisTeichman 2006
GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centresWilding 2021
Downstream effect
Pulsatile GH release matching physiological pattern; subsequent IGF-1 elevationIonescu 2006
Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021
Feedback intact?
Yes — short pulse preserves somatostatin negative feedbackIonescu 2006
Glucose-dependent insulin release preserves physiological feedback
Origin
Modified human GRF 1-29 with four substitutions (D-Ala²/Gln⁸/Ala¹⁵/Leu²⁷) for protease resistanceTeichman 2006
Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021
Antibody development
Not reported in short-term studies
—
02Dosage Protocols
Parameter
CJC-1295 (no DAC)
Semaglutide
Frequency
1–2× daily (pre-sleep ± morning)
Once weekly, same day each week
Lower / starter dose
50 mcg per dose
—
Evidence basis
Phase 1 (CJC-1295 with DAC); analog dataTeichman 2006Ionescu 2006
No-DAC variant is less studied directly; PK extrapolated from native GHRH.
FDA-approved · Phase 3 RCTsWilding 2021WEGOVY (semaglutide) injection 2021
Duration
8–12 weeks on / 4 off (anecdotal)
Indefinite for chronic indication
Discontinuation results in weight regain.
Reconstitution
Bacteriostatic water
Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.
Timing
Pre-sleep + fasted preferred
Any time of day, with or without food
Half-life
~30 minIonescu 2006
Short pulse vs CJC-1295-DAC (~8 days). Choose no-DAC for pulsatile, DAC for sustained.
~7 days (168 h)WEGOVY (semaglutide) injection 2021
Standard dose (weight, Wegovy)
—
2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021Wilding 2021
Titration schedule
—
0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks
Mitigates GI side effects.
04Side Effects & Safety
Parameter
CJC-1295 (no DAC)
Semaglutide
Injection site reaction
Erythema, mild pruritus
Mild erythema, pruritus
Flushing / headache
Common transient effect
—
Cortisol elevation
Minimal at standard doses
—
Prolactin elevation
Minimal
—
Glucose intolerance
Possible at high cumulative doses
—
IGF-1 elevation
Dose-dependent; monitor with chronic use
—
Cancer risk
Contraindicated in active malignancy (GH/IGF-1 axis)
—
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021
Hypoglycemia
—
Low risk as monotherapy; elevated when combined with sulfonylureas / insulin
Gallbladder events
—
Increased cholelithiasis
Heart rate
—
Modest ↑ resting HR (~2-4 bpm)
Absolute Contraindications
CJC-1295 (no DAC)
- ·Active malignancy or cancer history
- ·Pregnancy / breastfeeding
- ·Disrupted hypothalamic-pituitary axis
Semaglutide
- ·Personal or family history of medullary thyroid carcinoma
- ·Multiple endocrine neoplasia syndrome type 2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to semaglutide
Relative Contraindications
CJC-1295 (no DAC)
- ·Untreated diabetes
- ·Severe insulin resistance
Semaglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy (may worsen with rapid glycemic improvement)
05Administration Protocol
Parameter
CJC-1295 (no DAC)
Semaglutide
1. Reconstitution
Add 2 mL bacteriostatic water to 2 mg vial → 1 mg/mL = 100 mcg per 0.1 mL. Roll gently.
Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.
2. Injection site
Subcutaneous, abdomen or thigh. Rotate sites.
SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.
3. Timing
Pre-sleep preferred. Often combined with ipamorelin in the same syringe.
Once weekly, same day. Day can be changed if ≥2 days separate doses.
4. Storage
Lyophilised: room temp, protected from light. Reconstituted: refrigerate 2–8 °C, use within 30 days.
Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.
5. Needle
29–31G, 4–8 mm insulin syringe.
Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.
06Stack Synergy
CJC-1295 (no DAC)
+ Ipamorelin
StrongCJC-1295 (no DAC) and ipamorelin are the canonical "GHRH + GHRP" dual-axis stack at physiological timing. Both peak within 30 min and clear within 2 hours, producing a sharp, high-amplitude GH pulse closely resembling natural physiology. Preferred over the CJC-1295-DAC + ipamorelin stack when pulsatility (vs sustained elevation) is the goal.
- CJC-1295 (no DAC)
- 100 mcg SQ · pre-sleep
- Ipamorelin
- 200–300 mcg SQ · same injection
- Primary benefit
- Pulsatile GH stimulation, recovery, body composition
Semaglutide
+ Tirzepatide
WeakCombining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.
- Note
- Stack not recommended — choose one GLP-1 RA
- Primary benefit
- (none — additive toxicity, no synergy)